• Innovative approaches to the treatment of uterine leiomyoma

Innovative approaches to the treatment of uterine leiomyoma

HEALTH OF WOMAN. 2016.7(113):104–106 
 

Innovative approaches to the treatment of uterine leiomyoma


Zhylka N. Ya.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev


Innovation in the treatment of uterine fibroids mifepristone is a response to changes in scientific statements about the biological purpose of the reproductive function of women in modern terms, as it nedorealizatsiyi, causing pathogenic occurrence of uterine fibroids.


Key words: uterine leiomyoma, uterine fibroids, treatment, mifepristone.


REFERENCES

1. Fleagle JG, Assefa Z, Brown FH, Shea JJ. 2008. Paleoanthropology of the Kibish Formation, southern Ethiopia: Introduction. J. Hum. Evol. 55:360–365. http://dx.doi.org/10.1016/j.jhevol.2008.05.007; PMid:18617219

2. Goodman MJ, Estioko-Griffin A, Griffin PB, Grove JS. 1985. Menarche, pregnancy, birth spacing and menopause among the Agta women foragers of Cagayan province, Luzon, the Philippines. Ann. Hum. Biol. 12(2):169–177.

3. Flatt T, Heyland A. 2014. Mechanisms of life history evolution: the genetics and physiology of life history traits and trade-offs. Oxford University Press:504.

4. Strassmann BI. 1997. The biology of menstruation in Home sapiens: Total lifetime menses, fecundity, and nonsynchrony in a natural-fertility population. Curr. Anthropol. 38:123–129. http://dx.doi.org/10.1086/204592

5. Radzinskiy VE, Fatkullin IF, Bakanova AR, Dobretsova TA. 2014. Mioma matki: ot diskussiy k innovatsiyam. Prakticheskie rekomendatsii. M, Redaktsiya zhurnala StatusPraesens:16.

6. McDougall I, Brown FH, Fleagle JG. 2005. Stratigraphic placement and age of modern humans from Kibish, Ethiopia. Nature. 433:733–736. http://dx.doi.org/10.1038/nature03258; PMid:15716951

7. Tihomirov AL. 2013. Mioma. Patogeneticheskoe obosnovanie organosohranyayuschego lecheniya. M:320.

8. Savitskiy AG, Savitskiy GA, Mill KV. 2013. Fundamentalnyie mehanicheskie svoystva miometriya cheloveka. SPb, ELBP-SIb:144.

9. Politova AK, Puchkov KV, Kozlachkova ON. 2007. Rol lokalnogo gormonalnogo gomeostaza v razvitii dobrokachestvennyih giperplasticheskih protsessov matki. Sovremennyie tehnologii v diagnostike i lechenie ginekologicheskih zabolevaniy. Pod red. LV Adamyan. M:196–197.

10. Tihomirov AL, Lubnin DM. 2005. Optimizatsiya lecheniya bolnyih miomoy matki. Voprosyi ginekologii 4:5–6.

11. Hillard PA. 2014. Menstrual suppression: current perspectives. Int. J. Womens Health 6:631–637. http://dx.doi.org/10.2147/IJWH.S46680; PMid:25018654 PMCid:PMC4075955

12. Baird DD, Dunson DB. 2003. Why is parity protective for uterine fibroids? Epidemiology 14(2):247–250.

13. Ischenko AI, Botvin MA, Lanchinskiy VI. 2010. Mioma matki: etiologiya, patogenez, diagnostika, lechenie. M, Izdatelskiy dom Vidar-M:244.

14. Mauro A, Martelli A, Berardinelli P et al. 2014. Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation. PLoS One. 9(4):e95910.

15. Petrakova SA. 2009. Vozmozhnosti miomektomii v korrektsii reproduktivnogo zdorovya zhenschin s miomoy matki. Akusherstvo i ginekologiya 1:30–31.

16. Tihomirov AL, Ledenkova AA, Bataeva AE, Abyishova VG. 2012. Antagonistyi retseptorov progesterona v strukture kompleksnogo organosohranyayuschego lecheniya miomyi matki. Akusherstvo i ginekologiya 5:115–119.

17. Tristan M, Orozco LJ, Steed A et al. 2012. Mifepristone for uterine fibroids. Cochrane Database Syst. Rev. Issue 8:CD007687.

18. Карева ЕН. 2010. Мифепристон и миома матки. Фарматека. 14:18–30.

19. Eisinger SH, Bonfiglio T, Fiscella K et al. 2005. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive Gynecol. 12;3:227–233. http://dx.doi.org/10.1016/j.jmig.2005.01.022; PMid:15922980

20. Zvyichaynyiy MA, Vorontsova AV, Chilova AL, Fedotovskih IV. 2014. Giperplasticheskiy sindrom reproduktivnoy sistemyi u zhenschin v perimenopauze: taktika konservativnoy terapii i reabilitatsii. Ginekologiya 1:44–48.